Drug Type Monoclonal antibody |
Synonyms SP11285 |
Target |
Action modulators |
Mechanism ROR1 modulators(Inactive tyrosine-protein kinase transmembrane receptor ROR1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Preclinical | United States | 07 Nov 2022 | |
| Lung Cancer | Preclinical | United States | 07 Nov 2022 |






